Plain-English translation of NCT04248855 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Read our Celiac disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested , a new experimental medication designed to help people with celiac disease. Researchers studied whether the medication was safe and how well patients tolerated it when given as either a single dose or multiple doses over time. The trial involved adults with celiac disease who had been following a gluten-free diet for at least a year.
Currently, the only way to manage celiac disease is to strictly avoid gluten for life. This medication was being developed to offer a potential new treatment option that might help people with celiac disease, giving them more choices beyond dietary restriction alone.
Participants were split into two parts of the study. In the first part, some participants received a single dose of the medication at one of four different dose levels. In the second part, other participants received three doses of either the medication or a placebo (inactive substance) over time, allowing researchers to see how the treatment worked when given repeatedly. Throughout the trial, participants visited the clinic for monitoring and to check for any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States